country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-187572

Copy Link Print Information

KNI-10033

KNI-10033 is a HIV-1 protease inhibitor with a K_d value of 13 pM for both wild-type and pseudo-wild-type human HIV-1 protease. KNI-10033 can be used in studies related to HIV infection and acquired immunodeficiency syndrome (AIDS).

For research use only. We do not sell to patients.

CAS No.: 944476-53-3
Formula: C₄₀H₄₅N₅O₇S₂
Molecular Weight:771.94

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

KNI-10033 Chemical Structure

CAS No.: 944476-53-3

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

Viral Infection

KNI-10033 binds potently to wild-type HIV-1 protease with a K_d value of 13 pM^[1].
KNI-10033 (46-57 μM) binds tightly to pseudo-wild-type HIV-1 protease, with a K_d value of 13 pM at 25 °C^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Research Protocol for Infectious Diseases

Chemical Information

CAS No. 944476-53-3
Molecular Weight 771.94
Formula C₄₀H₄₅N₅O₇S₂
SMILES

O=C([C@H]1N(CSC1(C)C)C([C@@H](O)[C@@H](NC([C@H](CSC)NC(COC2=CC=CC3=C2C=CN=C3)=O)=O)CC4=CC=CC=C4)=O)N[C@H]5C6=CC=CC=C6C[C@H]5O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Freire E, et al. Do enthalpy and entropy distinguish first in class from best in class?. Drug discovery today. 2008 Oct;13(19-20):869-74.

[2]. Edwards AA, et al. Altered enthalpy-entropy compensation in picomolar transition state analogues of human purine nucleoside phosphorylase. Biochemistry. 2009 Jun 16;48(23):5226-38.

[3]. Kar P, et al. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease. The journal of physical chemistry. B. 2013 May 16;117(19):5793-805.

[4]. Lafont V, et al. Compensating enthalpic and entropic changes hinder binding affinity optimization. Chemical biology & drug design. 2007 Jun;69(6):413-22.

[5]. Scott DJ, et al. Extreme enthalpy‒entropy compensation in the dimerization of small solutes in aqueous solution. European biophysics journal : EBJ. 2024 Nov;53(7-8):373-384.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote